Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afimkibart phase 3 pediatric Crohn's disease treat-through study
PACTR202606682376312Phase 3Not yet recruiting
- Sponsor
- Roche
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Crohn's disease comparing Afimkibart with Placebo (2 arms). Primary endpoint: Efficacy of afimkibart in maintaining remission. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
afimkibart
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on PACTR202606682376312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202606682376312.